NCT06427304 Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure
| NCT ID | NCT06427304 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Gérond'if |
| Condition | Cardiac Amyloidosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 637 participants |
| Start Date | 2024-07-01 |
| Primary Completion | 2027-07-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 637 participants in total. It began in 2024-07-01 with a primary completion date of 2027-07-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Tne aim purpose of this observational, multicentre and propective study is to determine the prevalence of cardiac amyloidosis in geriatric patients aged 80 years and older hospitalized within the last 12 months for heart failure with left ventricular hypertrophy (septum ≥ 12 mm) on echocardiography
Eligibility Criteria
Inclusion Criteria: * Aged ≥ 80 years * Hospitalised for decompensation of heart failure in the last 12 months * Subjects with hypertrophy of the septum or left ventricle at cardiac echography (defined as ≥ 12 mm) * Subjects able to undergo a bone scintigraphy scan * Subjects willing to participate Exclusion Criteria: * Subjects refusing to participate * Subjects admitted to palliative care unit. * Subjects under guardianship * Subjects with a definite diagnosis of cardiac amyloidosis
Contact & Investigator
Olivier Hanon, MD PhD
STUDY CHAIR
Geriatric Department, Broca hospital
Frequently Asked Questions
Who can join the NCT06427304 clinical trial?
This trial is open to participants of all sexes, aged 80 Years or older, studying Cardiac Amyloidosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06427304 currently recruiting?
Yes, NCT06427304 is actively recruiting participants. Contact the research team at isabelle.dufour@gerondif.org for enrollment information.
Where is the NCT06427304 trial being conducted?
This trial is being conducted at Paris, France, Nantes, France, Poitiers, France, Rouen, France and 11 additional locations.
Who is sponsoring the NCT06427304 clinical trial?
NCT06427304 is sponsored by Gérond'if. The principal investigator is Olivier Hanon, MD PhD at Geriatric Department, Broca hospital. The trial plans to enroll 637 participants.